Loading...
•
Dec 31, 2024
Cytek Biosciences Q4 2024 Earnings Report
Estimated Revenue:$58.2M
+4.0% YoY
Estimated EPS:$0.049
+60.5% YoY
Key Takeaways
Cytek Biosciences reported a Q4 2024 revenue of $57.5 million, a 1.3% decrease compared to Q4 2023. Gross profit increased by 1.8% to $33.7 million, and net income was $9.6 million, including a non-recurring benefit. Adjusted EBITDA was $12.5 million.
Total revenue for the fourth quarter of 2024 was $57.5 million, a 1.3% decrease from the fourth quarter of 2023.
Gross profit for the fourth quarter of 2024 was $33.7 million, an increase of 1.8% compared to the fourth quarter of 2023.
Net income in the fourth quarter of 2024 was $9.6 million, including a $6.7 million after-tax non-recurring benefit.
Adjusted EBITDA in the fourth quarter of 2024 was $12.5 million compared to $9.9 million in the fourth quarter of 2023.
Revenue by Segment
Forward Guidance
Cytek Biosciences expects total revenue for the year ended December 31, 2025 to be in the range of $204 million to $212 million, representing growth of 2% to 6% over the year ended December 31, 2024, assuming no change in currency exchange rates.
Positive Outlook
- Revenue growth of 2% to 6% is expected.
- Revenue is expected to be in the range of $204 million to $212 million.
- The growth is calculated over the year ended December 31, 2024.
- The outlook assumes no change in currency exchange rates.
- The company is focused on growth strategy.
Challenges Ahead
- The revenue growth is only expected to be between 2% and 6%.
- The outlook is based on the assumption of stable currency exchange rates.
- Future performance is subject to various risks and uncertainties.
- The company's ability to achieve the expected revenue depends on market conditions.
Loading...
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...